Download PDF
Pharmacopsychiatry 2014; 47(06): 215-218
DOI: 10.1055/s-0034-1387700
Letter
© Georg Thieme Verlag KG Stuttgart · New York

Methylphenidate Intoxication: Somnolence as an Uncommon Clinical Symptom and Proof of Overdosing by Increased Serum Levels of Ritalinic Acid

M. Gahr
1   Department of Psychiatry and Psychotherapy III, University of Ulm, Ulm, Germany
,
M. A. Kölle
1   Department of Psychiatry and Psychotherapy III, University of Ulm, Ulm, Germany
› Author Affiliations
Further Information

Publication History

Publication Date:
14 August 2014 (online)

Also available at
    Permissions and Reprints

Abstract

There is considerable evidence for an increase of methylphenidate (MPH) abuse; thus, physicians might be confronted more frequently with MPH intoxications. Possible symptoms of intoxications with MPH are orofacial, stereotypic movements and tics as well as tachycardia, cardiac arrhythmias, arterial hypertension, hyperthermia, hallucinations and epileptic seizures. Here we report a patient who demonstrated somnolence as an uncommon clinical feature of MPH intoxication. The patient exhibited subnormal MPH serum levels (3 μg/l), however markedly increased serum levels of ritalinic acid (821 μg/l; inactive metabolite of MPH), that finally confirmed the initially suspected MPH intoxication. Due to the short half-life of orally administered MPH (t1/2~3 h) the sole measurement of MPH serum levels might be misleading concerning the proof of MPH overdosing in some cases. Parallel measurement of MPH and ritalinic acid is recommended in cases with suspected MPH intoxication and insufficient anamnestic data.

Key words

abuse - ADHS - neuroenhancement - stimulants - toxicology
 

  • References

  • 1 Berridge C, Devilbiss D.. Psychostimulants as cognitive enhancers: the prefrontal cortex, catecholamines, and attention-deficit/hyperactivity disorder. Biological Psychiatry 2011; 69: e101-e111
    CrossrefPubMedGoogle Scholar
  • 2 Arnsten A. Stimulants: Therapeutic actions in ADHD. Neuropsychopharmacology 2006; 31: 2376-2383
    CrossrefPubMedGoogle Scholar
  • 3 Buitelaar J, Montgomery S, van Zwieten-Boot B et al. Attention deficit hyperactivity disorder: guidelines for investigating efficacy of pharmacological intervention. Eur Neuropsychopharmacol 2003; 13: 297-304
    CrossrefPubMedGoogle Scholar
  • 4 Heal D, Smith S, Kulkarni R et al. New perspectives from microdialysis studies in freely-moving, spontaneously hypertensive rats on the pharmacology of drugs for the treatment of ADHD. Pharmacology Biochemistry and Behavior 2008; 90: 184-197
    CrossrefPubMedGoogle Scholar
  • 5 Schweri M, Skolnick P, Rafferty M et al. (3H)Threo-(+/−)-methylphenidate binding to 3,4-dihydroxyphenylethylamine uptake sites in corpus striatum: correlation with the stimulant properties of ritalinic acid esters. J Neurochem 1985; 45: 1062-1070
    CrossrefPubMedGoogle Scholar
  • 6 Wall S, Gu H, Rudnick G. Biogenic amine flux mediated by cloned transporters stably expressed in cultured cell lines: amphetamine specificity for inhibition and efflux. Mol Pharmacol 1995; 47: 544-550
    PubMedGoogle Scholar
  • 7 Deutsch H, Shi Q, Gruszecka-Kowalik E et al. Synthesis and pharmacology of potential cocaine antagonists. 2. Structure-activity relationship studies of aromatic ring-substituted methylphenidate analogs. Journal of Medical Chemistry 1996; 29: 1201-1209
    PubMedGoogle Scholar
  • 8 Gatley S, Pan D, Chen R et al. Affinities of methlyphenidate derivatives for dopamine, norpeinephrine and serotonin transporters. Life Sci 1996; 58: 231-239
    PubMedGoogle Scholar
  • 9 Unis A, Dawson T, Gehlert D et al. Auto radiographic localization of [3 H]methylphenidate binding sites in the brain. Eur J Pharmacol 1985; 113: 155-157
    CrossrefPubMedGoogle Scholar
  • 10 Ferris R, Tang F, Maxwell R. A comparison of the capacities of isomers of amphetamine, deoxypipradrol and methylphenidate to inhibit the uptake of tritiated catecholamines into rat cerebral cortex slices, synaptosomal preparations of rat cerebral cortex, hypothalamus and striatum and into adrenergic nerves of rabbit aorta. J Pharmacol Exp Ther 1972; 181: 407-416
    PubMedGoogle Scholar
  • 11 Kuczenski R, Segal D. Effects of methylphenidate on extracellular dopamine, seotonin and norepinephrine: comparison with amphetamine. Journal of Neurochemistry 1997; 68: 2032-2037
    PubMedGoogle Scholar
  • 12 Ramaekers J, Evers E, Theunissen E et al. Methylphenidate reduces functional connectivity of nucleus accumbens in brain reward circuit. Psychopharmacology (Berl) 2013; 229: 219-226
    CrossrefPubMedGoogle Scholar
  • 13 Volkow N, Ding Y, Fowler J et al. Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Archives of General Psychiatry 1995; 52: 456-463
    CrossrefPubMedGoogle Scholar
  • 14 Volkow N, Wang G, Fowler J et al. Association of methylphenidate-induced craving with changes in right-striato-orbitofrontal metabolism in cocaine abusers: implications in addiction. American Journal of Psychiatry 1999; 156: 19-26
    CrossrefPubMedGoogle Scholar
  • 15 Jorgensen F, Kodahl T. On the abuse of Ritalin. Ugeskrift for Laeger 1961; 123: 1275-1279
    PubMedGoogle Scholar
  • 16 Hahn H, Schweid A, Beaty H. Complications of injecting dissolved methylphenidate tablets. Archives of Internal Medicine 1969; 123: 659-659
    PubMedGoogle Scholar
  • 17 Willey R. Abuse of methylphenidate (Ritalin). New England Journal of Medicine 1971; 19: 464
    PubMedGoogle Scholar
  • 18 Forrester M. Methylphenidate abuse in Texas, 1998–2004. Journal of Toxicology and Environmental Health 2006; 69: 1145-1153
    PubMedGoogle Scholar
  • 19 Volkow N, Swanson J. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. American Journal of Psychiatry 2003; 160: 1909-1901
    CrossrefPubMedGoogle Scholar
  • 20 Chong S, Claussen C, Dafny N. Nucleus accumbens neuronal activity in freely behaving rats is modulated following acute and chronic methylphenidate administration. Brain Research Bulletin 2012; 87: 445-456
    CrossrefPubMedGoogle Scholar
  • 21 Sellings L, McQuade L, Clarke P. Characterization of dopamine-dependent rewarding and locomotor stimulant effects of intravenously-administered methylphenidate in rats. Neuroscience 2006; 141: 1457-1468
    CrossrefPubMedGoogle Scholar
  • 22 Schubert I, Köster I, Lehmkuhl G. The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK health insurance company in the German State of Hessen, 2000–2007. Deutsches Ärzteblatt International 2010; 107: 615-621
    PubMedGoogle Scholar
  • 23 Swanson J, Volkow N. Increasing use of stimulants warns of potential abuse. Nature 2008; 453: 586
    PubMedGoogle Scholar
  • 24 Frauger E, Nordmann S, Orleans V et al. Which psychoactive prescription drugs are illegally obtained and through which ways of acquisition? About OPPIDUM survey. Fundamental & Clinical Pharmacology 2012; 26: 549-556
    PubMedGoogle Scholar
  • 25 Dietz P, Striegel H, Franke A et al. Randomized response estimates for the 12-month prevalence of cognitive-enhancing drug use in university students. Pharmacotherapy 2013; 33: 44-50
    CrossrefPubMedGoogle Scholar
  • 26 Boyd C, McCabe S, Cranford J et al. Adolescents’ motivations to abuse prescription medications. Pediatrics 2006; 118: 2472-2480
    CrossrefPubMedGoogle Scholar
  • 27 Franke A, Bonertz C, Christmann M et al. Non-medical use of prescription stimulants and illicit use of stimulants for cognitive enhancement in pupils and students in Germany. Pharmacopsychiatry 2011; 44: 60-66
    Google Scholar
  • 28 Teter C, McCabe S, Cranford J et al. Prevalence and motives for illicit use of prescription stimulants in an undergraduate student sample. The Journal of American College Health 2005; 53: 253-262
    PubMedGoogle Scholar
  • 29 Borcherding B, Keysor C, Rapoport J et al. Motor/vocal tics and compulsive behaviors on stimulant drugs: is there a common vulnerability?. Psychiatry Research 1990; 33: 83-94
    CrossrefPubMedGoogle Scholar
  • 30 Klein-Schwartz W. Abuse and toxicity of methylphenidate. Current Opinion in Pediatrics 2002; 14: 219-223
    CrossrefPubMedGoogle Scholar
  • 31 Klein-Schwartz W, McGrath J. Poison centers’ experience with methylphenidate abuse in pre-teens and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry 2003; 42: 288-294
    CrossrefPubMedGoogle Scholar
  • 32 Faraj B, Israili Z, Perel J et al. Metabolism and disposition of methylphenidate-14C: studies in man and animals. J Pharmacol Exp Ther 1974; 191: 535-547
    PubMedGoogle Scholar
  • 33 Cantrell F, Ogera P, Mallett P et al. Fatal Oral Methylphenidate Intoxication with Postmortem Concentrations. J Forensic Sci 2014; 59: 847-849
    CrossrefPubMedGoogle Scholar
  • 34 Marti G, Fattinger K, Zimmermann H et al. Orofacial dyskinesia induced by nasal Ritalin(R) (methylphenidate) sniffing: a rare case report from Siwtzerland. Hum Exp Toxicol 2013; 32: 332-334
    CrossrefPubMedGoogle Scholar
  • 35 Bagdure D, Bhoite G, Reiter P et al. Dexmedetomidine in a child with methylphenidate intoxication. Indian J Pediatr 2013; 80: 343-344
    CrossrefPubMedGoogle Scholar
  • 36 Klampfl K, Quattländer A, Burger R et al. Case report: intoxication with high dose of long-acting methylphenidate (Concerta(®)) in a suicidal 14-year-old girl. Atten Defic Hyperact Disord 2010; 2: 221-224
    CrossrefPubMedGoogle Scholar
  • 37 Patrick K, Kilts C, Breese G. Synthesis and pharmacology of hydroxylated metabolites of methylphenidate. Journal of Medical Chemistry 1981; 24: 1237-1240
    CrossrefPubMedGoogle Scholar
  • 38 Aoyama T, Kotaki H, Sasaki T et al. Pharmacokinetics and Pharmacodynamics of (+)-threo-methylphenidate enantiomer in patients with hypersomnia. Clin Pharmacol Ther 1994; 55: 270-276
    CrossrefPubMedGoogle Scholar
  • 39 Wargin W, Patrick K, Kilts C et al. Pharmacokinetics of methylphenidate in man, rat and monkey. Journal of Pharmacology and Experimental Therapeutics 1983; 226: 382-386
    PubMedGoogle Scholar
  • 40 Patrick K, Mueller R, Gualtieri C et al. Pharmacokinetics and Actions of Methylphenidate. New York, NY: Raven; 1987
    Google Scholar
  • 41 Marchei E, Farré M, Pardo R et al. Correlation between methylphenidate and ritalinic acid concentrations in oral fluid and plasma. Clin Chem 2010; 56: 585-592
    CrossrefPubMedGoogle Scholar
  • 42 Levine B, Caplan Y, Kauffman G. Fatality resulting from methylphenidate overdose. J Anal Toxicol 1986; 10: 209-210
    CrossrefPubMedGoogle Scholar
  • 43 McCabe S, Teter C, Boyd C et al. Prevalence and correlates of illicit methylphenidate use among 8th, 10th, and 12th grade students in the United States, 2001. Journal of Adolescent Health 2004; 35: 501-504
    CrossrefPubMedGoogle Scholar